Charles River Laboratories (CRL) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-18) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion

Fiscal Year: 2025 (ended December 27, 2025)

One-line verdict: Charles River Laboratories reported a $142.2M net loss in 2025 — its first loss in recent history — after revenue declined 0.9% to $4.02B and operating income collapsed 89% from $227.3M to $25.2M, crushed by $210.9M in intangible asset impairments and $165.0M of Biologics Solutions goodwill impairment (the second year in a row with a goodwill charge — $215.0M was written off in 2024). The Manufacturing segment swung to a $184.3M operating loss from a $71.5M loss in 2024. The 10-K explicitly discloses the company is reviewing "potential strategic alternatives." The F grade reflects two mechanical fails: $3.1B in goodwill+intangibles equals 98% of equity, and cash of just $214M covers only 8% of $2.6B in debt. The M-Score is clean at -3.13 and operating cash flow of $737.6M was actually *above* 2024 ($734.6M), showing the cash engine survived the GAAP loss.

Revenue and Segment Performance: The Manufacturing Collapse

From the 10-K Consolidated Statements of Income (Loss):

Revenue is on a three-year decline: $4.13B → $4.05B → $4.02B. Operating income collapsed from $617.3M in 2023 to $25.2M in 2025 — a 96% decline in two years.

Segment breakdown:

The story is Manufacturing. The segment went from a $71.5M loss in 2024 to a $184.3M loss in 2025 — a $112.8M deterioration — on essentially flat revenue ($769M → $766M). This is where the $165M Biologics Solutions goodwill impairment landed, and where the $102M Cell Solutions intangible impairment hit RMS.

RMS operating margin collapsed from 13.8% to 5.3%, entirely due to the Cell Solutions intangible charge. DSA — the biggest segment at 60% of revenue — held its margin at 17.7%, down just 40bps, indicating the Safety Assessment franchise remains healthy even as overall revenue drifts.

Biologics Solutions Goodwill: The Two-Year Writedown

The audit report singles out Biologics Solutions as the CAM:

"Annual Goodwill Impairment Assessment - Biologics Solutions Reporting Unit. As described in Notes 1 and 10 to the consolidated financial statements, the Company's goodwill balance was $2,764.3 million as of December 27, 2025, a portion of which related to the Biologics Solutions reporting unit...Upon completion of the annual impairment test in fiscal 2025, management determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million."

Combined with the $215.0M impairment in fiscal 2024, $380M of Biologics Solutions goodwill has been written off in two consecutive years. This is the same pattern Cencora experienced with PharmaLex — management making forecasts, reality falling short, goodwill being marked down iteratively.

PwC's audit approach: "The fair value was determined using a weighted combination of a discounted cash flow model (an income approach) and sales and earnings multiples based on the guideline public company method and other market information (a market approach)."

The risk factor here is that a DCF-plus-market-multiple valuation of a business that's missed two consecutive forecasts has a high probability of another miss — and a third impairment is possible in 2026 if Biologics CDMO demand doesn't recover.

The $210.9M Intangible Asset Impairment: Cell Solutions

Separate from goodwill, CRL recorded a $210.9M intangible asset impairment in 2025. The 10-K and segment discussion attribute most of this ($102.0M) to the Cell Solutions asset group within RMS: "Operating income and operating income as a percentage of revenue decreased primarily due to a $102.0 million intangible asset impairment charge within the Cell Solutions asset group."

Cell Solutions provides "controlled, consistent, customized primary cells and blood components" for research use. This is a small but specialized business line, and the impairment suggests the acquisition goodwill and customer relationships carried over from earlier deals no longer support their carrying value.

The remaining ~$108.9M of intangible asset impairment spread across other units is less explicitly detailed in the MD&A sections reviewed.

Long-lived asset impairments on the cash flow statement total $259.1M in 2025, up from $51.8M in 2024 — a 5x increase.

Balance Sheet: Gradual Erosion

Intangible assets fell $383.4M — $210.9M from impairment, $179.1M from amortization, partially offset by additions. Goodwill fell $82.4M after the $165M impairment (offset by FX and other movements).

Total equity declined from $3.47B to $3.17B — the combined impact of the $142.2M net loss, $360.7M in share buybacks, and $145.6M in FX gains (OCI improved from -$317M to -$172M).

The engine's D1 check: "Goodwill+Intangibles $3.1B = 98% of equity. Over 50%." The D2 check: "Debt/EBITDA = 6.3x (>4x). Financial stress" — this is triggered because EBITDA collapsed along with operating income. On a normalized EBITDA basis (adding back the impairments), debt/EBITDA would be closer to 3.5-4x.

Cash Flow: The Saving Grace

Despite the GAAP loss, operating cash flow was essentially flat year-over-year:

OCF of $737.6M is actually the highest of the three years — confirming the GAAP loss is almost entirely non-cash. CapEx fell from $318.5M to $219.2M, giving FCF of $518.4M in 2025, its highest level in three years.

CRL deployed $360.7M on buybacks in 2025 — a 3x increase from 2024. At year-end the share count fell from 51.1M to 49.2M (3.8% reduction).

The engine's C1 check: "CFFO/NI = -5.11. Below 1.0" — true but mechanical (negative denominator). The C3 check: "Accruals ratio = -12.4%. Low accruals" — this is actually a strong signal that the GAAP loss is backed out by non-cash items.

Strategic Alternatives: An Important Disclosure

From Item 1A Risk Factors: "Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business."

The 10-K does not specify what strategic alternatives are under review — typical options include a sale, spin-off of Manufacturing, or private equity buyout. The fact that it's listed as a named risk factor means the review is substantive enough to potentially affect the business — customers and suppliers worry about continuity, and employees may leave.

The Manufacturing segment's two-year impairment pattern and $184M operating loss are the most likely targets of any restructuring.

The Non-Human Primate Supply Issue

One of CRL's most unique risk factors relates to research animal supply:

"Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business."

And more specifically: "In concert with legal matters affecting the Cambodian supply of non-human primates, the non-human primate supply chain globally has recently experienced constriction."

CRL supplies primate research models for pharmaceutical safety testing — a regulatory-required input for drug development. The Cambodian reference relates to a 2022 US federal indictment alleging that wild-caught NHPs were being laundered through Cambodian breeding facilities; CRL suspended Cambodian imports, which constrained global supply. This isn't directly tied to the 2025 impairments, but it's a persistent structural risk for the DSA segment.

Adjacent: "Activities conducted by us or any of our agents within these areas may be legally challenged and result in similar negative attention and action from environmental protection activists."

18-Point Screening

Revenue Quality

Expense Quality

Cash Flow Quality

Balance Sheet

Acquisition Risk

Beneish M-Score

Additional Scores: F-Score 1.08, Z-Score 1.79 (grey zone).

Key Risks from the 10-K

1. Strategic Alternatives Review — Item 1A explicitly names "Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business." This signals that the board has actively explored sale or separation options.

2. Biotech Funding Cycle — The 10-K mentions that demand volatility, credit loss risk, and reductions in government R&D funding can adversely affect the business. DSA — which is 60% of revenue and depends on biotech and pharma R&D spending — is in a multi-year downturn tied to the biotech funding freeze.

3. Contract Termination Risk — Item 1A: "We bear financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays." DSA safety assessment studies are long-running and can be canceled when customers pause programs.

4. Manufacturing Segment Losses — The $184.3M operating loss in 2025 on $766M of revenue is a -24% operating margin. Two consecutive years of Biologics Solutions goodwill impairment ($215M + $165M = $380M) plus the $102M Cell Solutions intangible impairment in 2025 means management has written down nearly $482M of acquired value in the manufacturing ecosystem in two years.

5. Non-Human Primate Supply Chain — The Cambodian NHP import ban has constricted global primate supply. Any further regulatory action or an animal rights injunction could limit DSA's ability to perform safety studies.

6. Cybersecurity — Item 1A: "We have in the past experienced and in the future could experience unauthorized access into our information systems."

7. Interest Rate and Leverage — Debt/EBITDA is elevated at 6.3x on reported EBITDA (lower on normalized basis). Interest expense of $107.0M consumed 425% of reported operating income in 2025.

8. Activist Pressure on Research Animals — Item 1A references "Negative attention from special interest groups may impair our business" — animal rights organizations have targeted CRL facilities historically.

Summary

Grade: F. Real business deterioration, but cash generation intact.

Charles River Laboratories is a 75-year-old drug development services company in the middle of a painful industry downturn. Biotech funding collapsed in 2022-2024, pharma customers paused programs, and CRL's revenue has declined for three consecutive years ($4.13B → $4.05B → $4.02B). Operating income collapsed 96% from $617M in 2023 to $25M in 2025. Two years in a row, management has taken non-cash impairment charges on Biologics Solutions ($215M in 2024, $165M in 2025), and the 2025 result also includes a $102M Cell Solutions intangible writedown.

Manufacturing is now losing $184M annually. The company is publicly reviewing "strategic alternatives."

And yet: operating cash flow of $737.6M in 2025 is actually *higher* than 2024. Free cash flow of $518.4M is the highest in three years. CapEx has been cut from $318M to $219M. The Beneish M-Score is -3.13, deeply in the safe zone. PwC's clean opinion finds no evidence of accounting shenanigans — the impairments are the company honestly marking down businesses that haven't met their original thesis.

The F grade reflects two hard fails:

The engine also flagged WATCH on D2 (Debt/EBITDA 6.3x) — this is mechanical. Normalize for the ~$376M of non-cash impairments and EBITDA rises toward the $600M range, making debt/EBITDA closer to 3.5x.

What to watch for 2026:

This is a company in transition. The F grade captures the mechanical balance sheet signals, but the underlying franchises — especially Safety Assessment, which still earns 17.7% operating margins — retain meaningful value. Investors need to price the strategic review outcome alongside the fundamentals.

**Disclaimer**: This report is based on Charles River Laboratories' 2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags. Grade F means major red flags were detected that require serious investigation before proceeding.